Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- AGO Study Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
TCG is a combination chemotherapy regimen comprising gemcitabine, paclitaxel, and carboplatin. It was developed by the AGO Study Group (Arbeitsgemeinschaft Gynaekologische Onkologie) as a first-line treatment for epithelial ovarian cancer, fallopian tube cancer, and related tumors. The regimen's mechanism of action involves the synergistic effects of its three components: paclitaxel, a taxane that stabilizes microtubules to inhibit cell division; carboplatin, a platinum-based agent that causes DNA cross-linking; and gemcitabine, a nucleoside analog that inhibits DNA synthesis by targeting ribonucleotide reductase and incorporating into DNA strands. Although evaluated in the large Phase III AGO-OVAR 9 trial, the TCG triplet did not show a survival advantage over the standard paclitaxel and carboplatin doublet and was associated with increased hematological toxicity.
- Other names
- Gemcitabine/Paclitaxel/CarboplatinGCP
02
Targets
RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on gemcitabine + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + paclitaxel + carboplatin.